Time is ticking on the bromodomain landscape

Where are they now four years on? A look at the BET/Bromodomain landscape

April 3, 2020

Insights on the Jounce-Celgene collaboration and ICOS agonism

Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape

July 24, 2019

TKIs are still alive and kicking!

Drugging the undruggable with creative approaches to molecule development

January 9, 2019

Can CytomX’s Probody checkpoint beat the competition?

Can we improve on the tolerability of the nivolumab-ipilimumab regimen by designing better a checkpoint inhibitor?

November 5, 2018

What did we learn from Neon at ESMO18?

Initial results from the neon NEO-PV-01 phase 1B trial presented by Dr Patrick Ott

October 30, 2018

Is blood TMB ready for prime time?

With new data on the blood-based TMB test at ESMO, what can we learn about this approach?

October 29, 2018

Why are the SOLO1 data so compelling?

A discussion about the impact of the olaparib on the PARPi niche based on the findings of the SOLO1 trial

October 26, 2018

5 Trends from ESMO18

New trends in early drug develoment and Developmental Therapeutics

October 24, 2018

ESMO18 Live Blog Day 4

Wins for Pharma, some shakeouts for small biotechs on manic Monday at #ESMO18

October 22, 2018

ESMO18 Live Blog Day 3

Highlights and lowlights from Munich

October 21, 2018

ESMO18 Live Blog Day 2

Highlights and lowlights from Day 2 of #ESMO18

October 20, 2018

ESMO18 Live Blog Day 1

Highlights from Day 1 of #ESMO18 in Munich

October 19, 2018

ESMO18 Preview 5 – A look at the evolving Renal Cell Carcinoma landscape

The changing face of renal cell cancer from several perspectives

October 16, 2018

ESMO18 Preview 4 Gems from the Poster Halls

A dozen poster abstracts to watch out for at ESMO18 on a wide range of topics...

October 11, 2018

ESMO18 Preview 3 Top 10 Oral Abstracts

Third ESMO18 preview on oral abstract presentations

October 8, 2018

New developments in neoantigen vaccines

A look a progress on NeoVax in GBM, RNA vaccines and even a novel CAR T cell therapy with a difference.

October 8, 2018

ESMO18 Preview 1 Late Breakers What To Watch Out For

ESMO18 Preview 1 - Late Breaking Abstracts to watch out for

September 26, 2018